Amarin Corporation plc · NASDAQ:AMRN
Amarin — Q4 2023 Earnings Presentation
11 slides from Amarin's earnings presentation, Feb 29, 2024
Slide 1: Fourth Quarter & Full Year 2023 Financial Results and Business Update Conference Call
Fourth Quarter & Full Year 2023 Financial Results and Business Update Conference Call Patrick Holt President & CEO Tom Reilly CFO February 29, 2024
Slide 2: Forward Looking Statements & Disclaimer
Forward Looking Statements & Disclaimer This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA® (VAZKEPA® in Europe), clinical and regulatory efforts and timelines, potential regulatory and pricing approvals, generic product launches, res
Slide 3: Today's Agenda
Today’s Agenda 01 Fourth Quarter & Full-Year 2023 Business Highlights & 2024 Priorities Patrick Holt, President & CEO 02 Fourth Quarter & Full-Year 2023 Financial Results Tom Reilly, CFO 03 Q&A Patrick Holt, President & CEO AMARIN, VASCEPA, VAZKEPA and REDUCE-IT are trademarks Tom Reilly, CFO of Ama
Slide 4: Fourth Quarter & Full Year 2023 Business Highlights and 2024 Priorities
01 FOURTH QUARTER & FULL YEAR 2023 BUSINESS HIGHLIGHTS AND 2024 PRIORITIES Patrick Holt, President & CEO
Slide 5: Our Strategy: Focus on Operational Momentum to Maximize Patient Uptake on VASCEPA/VAZKEPA
OUR STRATEGY: FOCUS ON OPERATIONAL MOMENTUM TO MAXIMIZE PATIENT UPTAKE ON VASCEPA/VAZKEPA EUROPE U.S. RoW Accelerate European Extend Product Maximize Patient Revenue and Lifecycle and Uptake via P&R Outcomes Drive Profit Partnerships 5
Slide 6: 2023 Business Highlights & 2024 Priorities
2023 BUSINESS HIGHLIGHTS & 2024 PRIORITIES EUROPE REST OF WORLD 2023: 2023: Delivered ~65% growth in Q4 vs Q3 ‘23 powered by Spain Secured 5 Rest of World regulatory approvals, including Secured pricing and reimbursement, launched VAZKEPA China (VHTG); advanced CVRR regulatory process in China
Slide 7: Fourth Quarter & Full Year 2023 Financial Results
02 FOURTH QUARTER & FULL YEAR 2023 FINANCIAL RESULTS Tom Reilly, CFO
Slide 8: Q4/FY 2023 Financial Results
Q4/FY 2023 FINANCIAL RESULTS Q4 ’23 Total Revenue of $75M 2023 Operating Expenses • USA Net Revenue: $65 million • $21M reduction in Total Operating Expenses • European Revenue: $1.5 million; ~65% increase versus Q3 2023 1H vs. 2H 2023 • ROW Revenue: $8M (includes Edding Supply Shipments & • On-trac
Slide 9: Continued Focus on Controlling Costs and Maximizing Cash
CONTINUED FOCUS ON CONTROLLING COSTS AND MAXIMIZING CASH Strong Cash Position; Six Consecutive Quarters of Positive/Neutral Cash Flow 325 +$8M $321M Full Year 2023 Cash Position 320 Cash Flow Positive +$10M versus 12/31/22 +$10M • Cash Balance of $321M as of 12/31/23; 315 • Cash Flow Positive $10M f
Slide 10: Q&A
03 Q&A Patrick Holt, President & CEO Tom Reilly, CFO
Slide 11: Thank You
Vascepa Vazkepa (icosapent ethyl) (icosapent ethyl) THANK YOU